vascular functions in myeloma patients during anti-tumor therapy

Conditions: Cardiooncology; Myeloma; Endothelial Dysfunction

Summary: treatment options for multiple myeloma have increased significantly over the last years with the approval of immunomodulatory drugs (imids) and proteasome inhibitors (pis). these therapies have markedly improved overall survival for these patients to a median of 5-7 years. due to the advanced age, the myeloma patient collective has a high prevalence of pre-existing cardiovascular comorbidities. in addition, the primary disease process contributes to cardiovascular complications. with the beginning of anti-tumor therapy, an increased incidence of cardiovascular complications in myeloma patients can be determined. this includes hypertension, left ventricular dysfunction, heart failure and both arterial and venous thromboembolic events. the detailed mechanism by which proteasome inhibitors and immunomodulatory agents lead to increased cardiovascular events is not established at this time. endothelial dysfunction, as a possible mechanism of cardiovascular toxicity, is difficult to assess. flow-mediated dilation (fmd) is an noninvasive method to measure endothelial function by assessing the change in the vasodilatative reserve of the brachial artery. several independent recent investigations implicate that vascular (endothelial) dysfunction precedes hypertension and heart failure. this has been related to a reduced level of metabolites of the l-arginine-nitric oxide (no) signaling pathway. hypothesis: 1. anti-myeloma therapy exert vascular toxicity by limiting endothelial function. endothelial function, assessed by the change in the vasodilatative reserve of the brachial artery (flow-mediated dilation = fmd) decreases after myeloma therapy. 2. patients with multiple myeloma have a limited endothelial function compared to a healthy control group. a total of 40 myeloma patients will be examined. measurements will be taken at baseline, 1 month and 6 month after myeloma therapy. patients should not have received chemotherapy for at least 3 months. furthermore a healthy sex- and age-matched control group will be examined.

treatment options for multiple myeloma have increased significantly over the last years with the approval of immunomodulatory drugs (imids) and proteasome inhibitors (pis). these therapies have markedly improved overall survival for these patients to a median of 5-7 years, many continue to live for more than 10 years. due to the advanced age, the myeloma patient collective has a high prevalence of pre-existing cardiovascular comorbidities. in addition, the primary disease process contributes to cardiovascular complications. with the beginning of anti-tumor therapy, an increased incidence of cardiovascular complications in myeloma patients can be determined. this includes hypertension, left ventricular dysfunction, heart failure and both arterial and venous thromboembolic events. proteasome inhibitors including bortezomib and carfilzomib, and immunomodulatory agents, e.g. lenalidomide, represent cornerstone therapies for multiple myeloma. the most common therapy choices are bortezomib-based therapy (vcd, vc) and carfilzomib-based therapy (krd, kd). induction therapy is given 4-6 cycles followed by autologous hematopoietic cell transplantation. thereafter, many patients receive consolidation therapy. in patients not eligible for autologous hematopoietic cell transplantation, a prolonged course of initial chemotherapy is typically administered. the proteasome inhibitor bortezomib is used predominately in the front line setting, while second-generation carfilzomib is used in relapsed/refractory disease. despite their efficacy, increased rates of cardiovascular complications occur in patients exposed to these particular therapies. higher incidences of cardiac adverse events including hypertension, arrhythmia, heart failure, ischemic heart disease and cardiomyopathy has been reported in patients receiving carfilzomib and bortezomib. immunomodulatory agents are known to increase the risk of venous thromboembolic disease particularly when combined with dexamethasone or other chemotherapy. furthermore, increased incidence of myocardial infarction (mi) and cerebrovascular events has been demonstrated in patients treated with lenalidomide. the mechanism of pi- and imid-associated cardiotoxicity is not fully elucidated. pis inhibit proteasome activity, leading to the accumulation of abnormal proteins which in turn activates apoptotic pathways in myeloma cells. imids bind cereblon, a component of the e3 ubiquitin ligase which promotes proteasome-mediated degradation of the transcription factors, ikzf1 and ikzf. it is unclear if the protein degradation properties of these drugs contribute to cardiotoxicity, although clinical features of the toxicity suggest endothelial cell injury and dysfunction. it is possible that cv events may be augmented when these two classes of medications are co-administered and further enhanced by the additional endothelial stress conferred by steroids. the detailed mechanism by which proteasome inhibitors and immunomodulatory agents lead to increased cardiovascular events is not established at this time. endothelial dysfunction, as a possible mechanism of cardiovascular toxicity, is difficult to assess. flow-mediated dilation (fmd) is an noninvasive method to measure endothelial function by assessing the change in the vasodilatative reserve of the brachial artery. several independent recent investigations implicate that vascular (endothelial) dysfunction precedes hypertension and heart failure. this has been related to a reduced level of metabolites of the l-arginine-nitric oxide (no) signaling pathway. hypothesis: 1. anti-myeloma therapy exert vascular toxicity by limiting endothelial function. endothelial function, assessed by the change in the vasodilatative reserve of the brachial artery (flow-mediated dilation = fmd) decreases after myeloma therapy. 2. patients with multiple myeloma have a limited endothelial function compared to a healthy control group. study design: a total of 40 myeloma patients will be examined. measurements will be taken at baseline, 1 month 6 month after myeloma therapy. patients should not have received chemotherapy for at least 3 months. furthermore a healthy sex- and age-matched control group will be examined. primary endpoint: • endothelial function, assessed by the change in the vasodilatative reserve of the brachial artery (flow-mediated dilation = fmd), between baseline and 1 month data secondary endpoints: * endothelial function, assessed by the vasodilatative reserve of the brachial artery (flow-mediated dilation = fmd) between baseline data in myeloma patients and control group * change of left ventricular pump function (3d-ef, global longitudinal strain) * alteration of echocardiographic parameters of diastolic dysfunction * change in dyspnea symptoms (nyha classification) * modification of cardiac biomarkers (nt-pro bnp, troponin) * change of circulating no-pool * change in metabolomics (biobank) * change in arterial stiffness and augmentation index * change of quality of life rated according to medical outcomes short-form survey, sf-36, minnesota living with heart failure questionnaire * change in blood pressure

Eligibility criteria:
included in the study are myeloma patients with planned bortezomib, carfilzomib and lenalidomide-based chemotherapy and 20 subjects from a healthy normal population. inclusion criteria: * age ≥ 18 years * written consent exclusion criteria: * severe pulmonary, valvular, or congenital heart disease with clinical dyspnoea symptoms * life expectancy less than 6 months * unstable angina pectoris or indication for coronary revascularization * valvular disease (aortic valve and mitral regurgitation greater than moderate, and aortic valve or mitral valve stenosis greater than moderate) * atrial fibrillation or flutter * chronic renal insufficiency (cockcroft-gault gfr \<30 ml / min) * severe cirrhosis (child-pugh b and c) * current or future indication for therapy with organic nitrates * leading non-cardiac cause of clinical dyspnea symptoms, such as high-grade obesity or lung disease in need of glucocorticoid therapy or oxygen therapy * other cause of clinical dyspnea symptoms, such as high-grade obesity or lung disease with need for glucocorticoid therapy or oxygen therapy

Keywords: myeloma flow mediated dilation endothelial dysfunction proteasome inhibitors